Survival of patients with prostate cancer in a hospital Bogotá, Colombia 2008-2014
Article Sidebar
Main Article Content
Abstract
Prostate cancer is currently one of the main pathologies that affects men. The objective of this article was to estimate the survival of patients with intermediate and high risk prostate cancer belonging to the special health regimen. A cohort study was conducted that estimates the survival function with the Kaplan-Meier method, the Hazard ratio (HR) as a function of explanatory variables using a Cox regression model. The patients included were diagnosed by urology and / or confirmed with diagnostic support, patients treated for prostate cancer in another institution, primary tumors other than the prostate, and those who consulted for a second medical opinion were not included. Intermediate-risk patients survive 90% to both 5 and 7 years, and high-risk patients survive 35% and 30% to 5 and 7 years, respectively, with a median of 28 months. This study allowed us to conclude that survival in patients classified as intermediate risk is similar to national and international ones, however, in high-risk patients, survival is lower than in other countries.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Ribal M, Mellado B. Guías de consenso para el manejo del cáncer de próstata resistente a castración en Catalunya. UOC; 2014.
Campá J, Mar B, Extramiana J, Arróspide A, Mar J. Supervivencia del cáncer de próstata avanzado en España según escala de Gleason, edad y estadio. Actas Urológicas Españolas. 2016 Oct; 40(8): 499-506. Doi: https://doi.org/10.1016/j.acuro.2016.03.0083
National Cancer Institute. Prostate Cancer Prevention (PDQ®)–Health Professional [Internet] [citado 15 sep 2019]. Disponible en: https://www.cancer.gov/types/prostate/hp/prostate-prevention-pdq
Pow-Sang M, Destefano V, Astigueta J, Castillo O, Gaona J, Santaella F, et al. Cáncer de próstata en Latinoamérica. Actas Urol Esp. 2009 Dic; 33(10): 1057-61. Doi: https://doi.org/10.1016/S0210-4806(09)73181-X
Ospina M, Huertas J, Montaño J, Rivillas J. Observatorio Nacional de Cáncer Colombia. Fac. Nac. Salud Pública [revista en la Internet]. 2015 May; 33(2): 262-76. Disponible en: https://revistas.udea.edu.co/index.php/fnsp/article/view/19044
Gutiérrez P, González S, Conde V. Influencia del protocolo diagnóstico y la edad en la tasa de incidencia de cáncer de próstata en Castilla y León según el registro nacional de 2010. Actas Urol Esp. 2021; 45(5): 383-90. Doi: https://doi.org/10.1016/j.acuro.2020.11.007
Lacny S, Wilson T, Clement F, Roberts D, Faris P, Ghali W, et al. Kaplan–Meier survival analysis overestimates cumulative incidence of health-related events in competing risk settings: a meta-analysis. Journal of Clinical Epidemiology. 2018 Oct; 93: 25-35. Doi: https://doi.org/10.1016/j.jclinepi.2017.10.006
Colombia. Ministerio de Salud. Resolución Número 8430 de 1993 [Internet]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.PDF
Montero Granados R. Modelos de regresión lineal múltiple [Trabajo de grado Economía Aplicada]. España: Universidad de Granada. Facultad Ciencias Empresariales; 2016.
Allemani C, Weir H, Carreira H, Harewood R, Spika D, Wang X, et al. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (Concord-2). Lancet. 2015; 385(9972): 977-1010. Doi: https://doi.org/10.1016/S0140-6736(14)62038-9
Villegas C, Chacón J, Sánchez T. Sobrevida en cáncer de próstata de una población del centro de Colombia 1997-2012. Acta Médica Colombiana. 2015; 40(2): 101-8. Doi: https://doi.org/10.36104/amc.2015.447
Restrepo J, Bravo L, García-Perdomo H, García L, Collazos P, Carbonell J. Incidencia, mortalidad y supervivencia al cáncer de próstata en Cali, Colombia, 1962-2011. Salud Pública Mex. 2014; 56(5): 440-7. Doi: https://doi.org/10.21149/spm.v56i5.7369
Yossepowitch O, Eggener S, Serio A, Carver B, Bianco F, Scardino P, et al. Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical Prostatectomy. Eur Urol. 2008; 53(5): 950-9. Doi: https://doi.org/10.1016/j.eururo.2007.10.008
Angulo J, Romero I, Díaz M, Enrech S, Díez R, Molina T. Supervivencia del cáncer de próstata resistente a la castración en la práctica clínica y el papel del tratamiento. Rev Colombiana de Cancerología. 2017 Jun; 21(2): 95-103. Doi: http://dx.doi.org/10.1016/j.rccan.2017.03.002
Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Kitsukawa S, et al. Long-term oncological outcome inmen with T3 prostate cancer: Radical prostatectomy versus external-beam radiation therapy at a single institution. Int J Clin Oncol. 2014; 19: 1085-91. Doi: https://doi.org/10.1007/s10147-013-0654-2
Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, Briganti A, et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis. Int J Urol. 2012; 19(9): 836-44. Doi: https://doi.org/10.1111/j.1442-2042.2012.03052.x
Neeple K, Stephenson A, Kallogjeri D, Michalski J, Grubb I, Strope S, et al. Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or
Brachytherapy in Men Without Comorbidity. European Urology. 2013; 64(3): 372-8. Doi: https://doi.org/10.1016/j.eururo.2013.03.005
DeVita V, Hellman S, Rosenberg S. Cancer Principles & Practice of Oncology. 6.a edición. [Internet]. Philadelphia: Williams & Wilkins Publishers; 2011. Disponible en: https://oncouasd.files.wordpress.com/2014/09/cancer-principles-and-practice-of-oncology-6e.pdf
Rodríguez A, Gómez F, Álvarez J, Carballido J, Palou J, Solsona E, et al. Factores que predicen el desarrollo de metástasis óseas por cáncer de próstata: recomendaciones de seguimiento y opciones terapéuticas. Actas Urol Esp. 2014; 38(4): 263-9. Doi: http://dx.doi.org/10.1016/j.acuro.2013.09.002
Ferrís J, García J, Berbel O, Ortega J. Factores de riesgo constitucionales en el cáncer de próstata. Actas Urol Esp. 2011; 35(5): 282-8. Doi: https://doi.org/10.1016/j.acuro.2010.12.009
Segarra J, Millán F, Palou J, Villavicencio H. Factores pronósticos y tablas predictivas del cáncer de próstata clínicamente localizado. Actas Urol Esp. 2006; 30(6): 567-73. Doi: https://doi.org/10.1016/S0210-4806(06)73496-9
Pound C, Partin A, Epstein J, Walsh P. Prostate-Specific Antigen After Anatomic Radical Retropubic Prostatectomy: Patterns of Recurrence and Cancer Control. Urol Clin North Am. 1997 May; 24(2): 395-406. Doi: https://doi.org/10.1016/S0094-0143(05)70386-4
Oncology, American Society of Clinical. Cáncer de próstata: Estadísticas [Internet] [citado 11 abr 2020]. Disponible en: https://www.cancer.net/es/tipos-de-c%C3%A1ncer/c%C3%A1ncer-de-pr%C3%B3stata/estad%C3%ADsticas